Nutrition Rehabilitation in Oncopathology: Opportunities and Prospects

Abstract

Nutritional corrective support is an integral component of rehabilitation programs in the perioperative period for oncological pathology. The aim of this study was to evaluate the effectiveness of including remaxol in the rehabilitation treatment regimen for gastroenterological cancer patients. Material and methods. The treatment results of 42 patients with gastric outlet tumors and small intestine tumors were retrospectively analyzed. Remaxol was included in the adjuvant therapy for patients in the main (I, N=22) group: intravenously 400 ml at a rate of 40–80 drops/min (2–4 ml/min) once a day for 10 days. Patients in the comparison group (II, N= 20) received traditional nutritional therapy. The study used both traditional clinical diagnostic methods and methods for assessing the risks of nutritional deficiency and the rehabilitation potential of the body, its adaptive capabilities, and disease prognosis. Results. All patients showed signs of severe nutritional deficiency, endotoxemia, intoxication, and hepatotoxicity. Liver detoxification parameters were better in patients who received remaxol as an adjuvant therapy than in the comparison group. Conclusions. Cancer patients with a high nutritional risk and moderate to high nutritional deficiency are at a higher risk of developing toxic complications requiring adjuvant therapy. The inclusion of remaxol in adjuvant therapy reduced the severity of hepatotoxic reactions in these patients. The data obtained made it possible to recommend its inclusion in treatment regimens for patients with this pathology.